Quoin Pharmaceuticals Ltd. (QNRX) Form 8-K — Nov 4, 2026
Quoin Pharmaceuticals (QNRX) signed a sales agreement with Leerink Partners on November 4, 2026 to run an at-the-market equity program for its ADSs, with each ADS representing 35 ordinary shares. Leerink acts as agent, earning 3.0% of gross proceeds, and sales will be made on Nasdaq under a Form S-3 shelf (File No. 333-299668) declared effective the same day. No dollar cap on the program is disclosed beyond the registration statement limits.
Key figures
- Ads structure
- Each ADS represents 35 ordinary shares
- Agent commission
- 3.0% of gross sale proceeds
- Registration statement
- Form S-3 File No. 333-299668, declared effective November 4, 2026
- Non affiliate float value
- $33,090,228.60
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.